Trial Profile
A Phase 2, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Determine Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Subjects With Stage 4 and Stage 5 Kidney Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Ibutamoren (Primary)
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- 18 May 2018 New trial record